Seminars in Fetal & Neonatal Medicine
Volume 14, Issue 4 , Pages 218-221, August 2009

Parvovirus B19 infection

Department of Medicine, Solna, Unit of Infectious Diseases, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, B2:00, SE-17176 Stockholm, Sweden

published online 24 February 2009.

Summary 

Human parvovirus B19 (B19) is common in society. Among adults, more than 50% have contracted the infection and immunity is believed to last lifelong. Infection occurs in a few percent of pregnancies, and albeit rare it can then cause fetal anemia, non-immune fetal hydrops and fetal death. Among cases with fetal demise, B19 is found in significant numbers, especially in the second and third trimesters of pregnancy. There is no specific treatment or prophylaxis available against B19 infection, but counseling of non-immune mothers and active monitoring of confirmed maternal infections with intervention to correct fetal anemia is likely to decrease mortality. Passive immunization also has potential to resolve fetal complications, but needs further study.

Keywords: Congenital infection, Erythrovirus, Human parvovirus B19, Pregnancy, Prenatal diagnosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1744-165X(09)00008-0

doi:10.1016/j.siny.2009.01.007

Seminars in Fetal & Neonatal Medicine
Volume 14, Issue 4 , Pages 218-221, August 2009